ClinicalTrials.gg
RecruitingNCT06854809Updated Jun 18, 2025

Cognitive Functional Therapy Versus Exercises for Chronic Shoulder Pain

An interventional study of Cognitive functional therapy and Therapeutic exercise in Chronic Shoulder Pain, sponsored by Universidade Federal de Sao Carlos. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Universidade Federal de Sao Carlos · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Shoulder Pain with a site in Brazil — 2 open to participants now, 2 under way, none of them phase 3. Shoulder Pain · Brazil.

Planned enrollment
2nd of 21
148 · median 64
Started
2025
with 2 others
No phase
19 of 21
2 open now
Registered
20th of 21
by date
Lead sponsor
5 of 21
Universidade Federal de Sao Carlos

Among the 21 studies in Shoulder Pain with a site in Brazil, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2025, is one of 19 with no phase, and was the 20th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

2 of the 21 studies in Shoulder Pain with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Shoulder Pain with a site in Brazil, or all of them as a file.
02

Study summary

The objective of this clinical trial is to determine whether cognitive functional therapy is superior to therapeutic exercises for the treatment of chronic shoulder pain. The main questions it aims to answer are:

Is cognitive functional therapy superior to therapeutic exercises for pain and disability in individuals with chronic shoulder pain? Is cognitive functional therapy superior to therapeutic exercises for functionality and psychosocial factors?

Participants will:

Receive 4 to 8 sessions of cognitive functional therapy once a week for four to eight weeks.

Follow a therapeutic exercise protocol for eight weeks with a frequency of twice per week.

Read the detailed description

This will be a randomized controlled trial, single-blind, with two parallel groups. 148 individuals with chronic shoulder pain will be randomly assigned to one of two groups: Cognitive functional therapy (CFT) or therapeutic exercises. The interventions will last between four and eight weeks, with the CFT group receiving therapy once a week and the therapeutic exercise group receiving sessions twice a week for eight weeks. The primary outcomes will be pain intensity and disability, while the secondary outcomes will include specific function, kinesiophobia, self-efficacy, sleep quality, treatment expectations, perception of change, treatment satisfaction and exercise adherence.

03

Conditions studied

  • Chronic Shoulder Pain

Browse trials for

Keywords

  • shoulder pain
  • Psychosocial Rehabilitation
  • exercise therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals of both sexes, aged between 18 and 65 years, will be included if they have had shoulder pain for at least 3 months and report a pain intensity of at least 3 points on the Numeric Pain Rating Scale (NPRS) at rest or during arm movement. Additionally, they must have a minimum score of 20 points on the Shoulder Pain and Disability Index (SPADI).

Exclusion criteria

Exclusion Criteria:

Individuals will not be included if they have adhesive capsulitis, defined as a loss of more than 50% of passive shoulder range of motion in external rotation; previous shoulder surgery; a history of shoulder fracture; systemic musculoskeletal diseases (e.g., rheumatoid arthritis, fibromyalgia); shoulder pain reproduced by active or passive cervical spine movement; signs of glenohumeral instability identified by a positive sulcus test or a positive apprehension test indicating laxity in the glenohumeral joint; self-reported systemic disease; a positive drop arm test; pregnancy; active cancer treatment; neurological diseases; cognitive impairments; injection within three months prior to the intervention; or physical therapy in the three months preceding the study.

Participants will be discontinued from the study if they experience fractures, surgeries, musculoskeletal or neural injuries that prevent access to treatment, or receive corticosteroid injections during the treatment or follow-up period.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Cognitive functional therapy

    Behavioral: Cognitive functional therapy

  • Active comparator
    Therapeutic exercise

    Other: Therapeutic exercise

Interventions

  • BehavioralCognitive functional therapy

    The intervention consists of a Cognitive-Functional Therapy (CFT) program for individuals with shoulder pain, conducted by trained physiotherapists (106 hours of training) under the supervision of an expert with over 8 years of experience. CFT adopts a biopsychosocial approach and is structured into three main components: Making Sense of Pain - A cognitive component aimed at reinterpreting dysfunctional beliefs about pain through a reflective process based on the patient's life history, promoting understanding and self-efficacy. Graded Exposure with Control - Gradual exposure to functional activities, aiming to modify maladaptive associations between movement and pain, fostering the development of movement confidence. Lifestyle Change - Discussion and implementation of strategies to promote a healthy lifestyle, including physical activity, sleep habits, and stress management. All three components are integrated from the first session, with initial focus on building the therapeutic all.

  • OtherTherapeutic exercise

    Participants in the Therapeutic Exercises Group will engage in individualized exercises targeting the scapulothoracic musculature and rotator cuff. The exercises, performed bilaterally, include lateral arm rotation, T, W, wall hand slide, and diagonal arm movement upwards. Each participant will be guided by one of two physiotherapists, randomly assigned. The exercises will follow a protocol consisting of 3 sets of 12 repetitions, with 1-minute rest between sets, using progressively resistant Thera-Bands®. Resistance will increase when pain is ≤2 on the Numerical Rating Scale and perceived exertion is \<3 on the Borg Scale. The protocol was designed based on scientific literature and shoulder pain treatment guidelines to address muscle activation deficits and rotator cuff and scapulothoracic imbalances.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    The intensity of shoulder pain will be assessed during arm movement in which the patient reports, pain using the Numeric pain rating scale (NPRS). The scale consists of an 11-point ordinal system, ranging from 0 to 10, where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  2. Shoulder disability

    Disability will be assessed using the Shoulder Pain and Disability Index (SPADI). The instrument is self-administered and consists of 13 items divided into 2 subscales (5 items for pain; 8 items for disability) and each item is scored from 0 to 10 points. The final score ranges from 0 to 100, with higher scores indicating greater shoulder disability.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

Secondary outcomes

  1. Patient Specific Function

    The Patient Specific Functional Scale (PSFS) will be used to assess the patient's specific functionality. Patients will be asked to identify up to three important activities that they are having difficulty with or are unable to perform due to their condition. Furthermore, patients must classify, on a scale of 11 points (ranging from 0 "unable to perform activity" to 10 "able to perform activity".

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  2. Kinesiophobia

    Kinesiophobia will be assessed by the Tampa Kinesiophobia Scale 11 (TSK-11). The TSK is an instrument used to measure fear of movement. It is a self-administered questionnaire and presents 11 questions related to pain and intensity of symptoms. The score ranges from 11 to 44 points, in which higher scores indicate higher levels of kinesiophobia.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  3. Pain Self-Efficacy

    Self-efficacy will be assessed using the Pain Self-Efficacy Questionnaire (PSEQ). This is a 10-item self-report questionnaire that measures the degree of self-confidence in performing certain activities. Each item is rated on a 7-point Likert scale (0 = not at all confident; 6 = completely confident), with higher scores reflecting greater self-confidence.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  4. Sleep Quality

    Sleep quality will be assessed using the Insomnia Severity Index (ISI). This is a scale that assesses the nature, intensity, and impact of insomnia experienced in the last month. The self-report instrument consists of 7 questions, answered using a Likert scale ranging from 0 (no severity) to 4 (high severity). The total score ranges from 0 to 28, classified as follows: no insomnia (0-7), mild insomnia (8-14), moderate insomnia (15-21), and severe insomnia (22-28).

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  5. Expectations with Treatment

    The patient's expectations regarding the treatment will be assessed by asking the question "How much do you expect your shoulder to improve at the end of the treatment?". The score will be measured on a 7-point Likert scale, with 1 being "worst possible" and 7 being "completely recovered". The assessment will be made before the intervention begins.

    Time frame: Baseline

  6. Perception of Change

    The individual's perception of changes in health status over time will be measured using the Global Change Assessment Scale. The score varies from 15 points, with -7 being "a very significant worsening", 0 indicating "no change" and +7 "a very significant improvement"

    Time frame: 4-week, at the end of treatment (8-week), and 12-week follow-up

  7. Satisfaction with treatment

    The individual's satisfaction with the treatment will be measured using the Global Rating of Change Scale. The score varies from 15 points, with -7 being "the worst possible satisfaction", 0 indicating "no change" and +7 "the best possible satisfaction".

    Time frame: At the end of treatment (8-week), and 12-week follow-up

  8. Exercise adherence

    To assess exercise adherence, sections B and C of the Brazilian version of the Exercise Adherence Rating Scale (EARS-Br) will be used. Section B consists of 6 items rated on a 5-point Likert scale ranging from 0 ("strongly agree") to 4 ("strongly disagree"). This section aims to measure the participant's level of adherence to the recommended exercises. The total score ranges from 0 to 24 points, with scores equal to or greater than 17 indicating good adherence to the home exercise program. Section C consists of 9 items, also organized on a 5-point Likert scale (0 = "strongly agree"; 4 = "strongly disagree"). This section explores factors that influence exercise adherence, divided into barriers (items 1, 2, 3, 8, and 9) and facilitators (items 4, 5, 6, and 7).

    Time frame: 4-week, at the end of treatment (8-week), and 12-week follow-up

07

Study locations

1 of 1 sites recruiting
  • Universidade Federal de Sao Carlos
    São Carlos, SP 13568-110, Brazil
    Recruiting
    • Universidade Federal de São Carlos · Contact
08

References and documents

Individual participant data

Plan to share: Yes — The individual participant data will be shared under request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: From December 1, 2027, to December 1, 2028, the data will be available for one year.

Access criteria: The data will be shared with anyone who requests it via the responsible researcher's email.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jun 2027, 23 months later.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 23 months is above that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartEst.
Jul 2025
Primary completionEst.
Jun 2027
CompletionEst.
Mar 2029
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06854809
Lead sponsor
Universidade Federal de Sao Carlos
Responsible party
Matheus Dias Gregorio (Principal Investigator, Universidade Federal de Sao Carlos) — Principal investigator
First posted
Mar 3, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 18, 2025

Study contacts

Matheus Dias Gregorio
Contact
matheusgregorio@estudante.ufscar.br
+55 (14) 99679-3919

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion